Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

Susavion Biosciences, Inc., is a privately-owned company that was formed to advance technology based on discovery of multi-valent, bio-active peptides that mimic carbohydrate ligands of lectin-type receptors suitable for use as therapeutic modulators of the immune system.

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

User Experience Monitoring

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Shanghai Enkai Cell Technology Co., Ltd., established on 2020-03-03, Business scope includes licensed projects:Drug retail;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Engaged in the field of biomedicine and biotechnology(remove human stem cells,Development and application of genetic diagnosis and treatment technology)technology development,technology transfer,technical consulting,Technical Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Hebei Life Origin Biotechnology Co., Ltd. is a Chinese private company that engages in stem cell production.

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.

Morinaga Milk Industry Co., Ltd. engages in the production and distribution of dairy products. Its operations are carried out through the following segments: Food Products and Others. The Food Products segment engages in the production and sale of milk, dairy-based beverages, yogurt, desserts, condensed milk, powdered milk, butter, cheese, ice cream, non-dairy beverages (juice, tea, coffee), and clinical liquid diets. The Others segment provides the real estate leasing services. It also engages in the manufacture and sale of animal feeds; design and construction of plant equipment. The company was founded on September 1, 1917 and is headquartered in Tokyo, Japan.

Jinan New Times Pharmaceutical Technology Co., Ltd., established on 2015-10-16, Business scope includes traditional Chinese medicine,Technology Development of Health Food,technology transfer,technical consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Qingdao Medisys Biotechnology Co., Ltd., established on 2012-08-15, Business scope includes import and export of goods,Technology Import and Export(Except for items prohibited by laws and administrative regulations,Projects restricted by laws and administrative regulations will be operated after obtaining permission),Biotechnology R&D,Technical Consulting and Technical Services,Wholesale and retail:chemical reagent(Free of Hazardous Chemicals),laboratory consumables,equipment,Office Supplies,Computer hardware and software and accessories,electronic product,Photographic camera equipment,communication equipment(Does not include radio transmission and ground satellite reception equipment),electronics,Wujinjiaodian,medical instruments,R&D of cosmetics,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

IPMBiotech focuses on the development and application of precision medical technology and cell therapy technology.

Miltenyi Biotec, Inc. provides equipment and related services for biomedical research. The company was founded on April 2, 1992 and is headquartered in Auburn, CA.

SMT Bio Co., Ltd. is a company headquartered in Seoul, the South Korea, specializing in commercial physical and biological research. It was founded in 2015. Yong-Yoon Jung is currently the CEO of the firm.

Medicell Co., Ltd. is a South Korean company located in Hwasun-gu that engages research and development of skin care products. The firm was founded in 2009. Jung-Hyun Kim is the current CEO of the company.

Yuanqi Biotechnology Shanghai Co Ltd. is a private company headquartered in China that develops antibodies, antigen-binding fragments variants and bispecific antibodies in the prevention and treatment of tumors.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.